BOSTON, March 24 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has received a purchase order for the MammoView(TM) line of surgical endoscopy instruments from Sharp Healthcare, one of San Diego's leading healthcare networks. Sharp Healthcare has 14,000 employees and 2600 affiliated doctors. Sharp was named the best integrated healthcare network in the State of California, where, in 2007, it won the Malcolm Baldridge Quality Award.
Sharp HealthCare is a not-for-profit integrated regional health care delivery system based in San Diego, California. Sharp includes four acute-care hospitals, three specialty hospitals and two medical groups, plus a full spectrum of other facilities and services. As San Diego's health care leader, Sharp has an unwavering commitment to excellence and passion for caring.
"We are proud to be a supplier to such a prestigious healthcare provider. The Sharp Healthcare Network has been serving the San Diego community for over 50 years and we look forward to creating a long term relationship with the entire Sharp organization," stated Bob Segersten, President of Solos Endoscopy, Inc.
For more information on Sharp Healthcare, please visit http://www.sharp.com/en/about/.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2009 PR Newswire.
All rights reserved